Findings from the phase III GIMENA ALL2820 study, focusing on "the superiority of a frontline chemotherapy-free targeted and immunotherapeutic approach over conventional treatment in adult patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia" was recently published in the New England Journal of Medicine. The authors of the study also acknowledged the challenges in obtaining marketing authorization for patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia, "with overall costs of this new regimen [remaining] beyond the budget of many healthcare systems."
Click here to read more about this study.
Sources mentioned:
- Chiaretti S, Piciocchi A, Skert C, et al. for the GIMEMA Investigators. Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL . N Engl J Med 2026;395(15):1483-1494.
- Fielding AK. Chemotherapy-free Treatment of Ph-Positive ALL . N Engl J Med 2026;395(15):1542-1544.
